These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21167011)

  • 1. Enigmatic role of lipoprotein(a) in cardiovascular disease.
    Anuurad E; Enkhmaa B; Berglund L
    Clin Transl Sci; 2010 Dec; 3(6):327-32. PubMed ID: 21167011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk.
    Discepolo W; Wun T; Berglund L
    Pathophysiol Haemost Thromb; 2006; 35(3-4):314-21. PubMed ID: 16877880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a): an elusive cardiovascular risk factor.
    Berglund L; Ramakrishnan R
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2219-26. PubMed ID: 15345512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein.
    Saeed A; Virani SS
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1099-1112. PubMed ID: 28930591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) catabolism: a case of multiple receptors.
    McCormick SPA; Schneider WJ
    Pathology; 2019 Feb; 51(2):155-164. PubMed ID: 30595508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current therapies for lowering lipoprotein (a).
    van Capelleveen JC; van der Valk FM; Stroes ES
    J Lipid Res; 2016 Sep; 57(9):1612-8. PubMed ID: 26637277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) and apolipoprotein(a) in a New World monkey, the common marmoset (Callithrix jacchus). Association of variable plasma lipoprotein(a) levels with a single apolipoprotein(a) isoform.
    Guo HC; Michel JB; Blouquit Y; Chapman MJ
    Arterioscler Thromb; 1991; 11(4):1030-41. PubMed ID: 1829630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers?
    Koschinsky ML
    Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):267-78. PubMed ID: 17378772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.
    Reyes-Soffer G; Westerterp M
    Pharmacol Res; 2021 Jul; 169():105689. PubMed ID: 34033878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor?].
    de Brouckère V; Liénart F; Ducobu J
    Rev Med Brux; 2010; 31(3):171-6. PubMed ID: 20687444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
    Tsimikas S; Brilakis ES; Miller ER; McConnell JP; Lennon RJ; Kornman KS; Witztum JL; Berger PB
    N Engl J Med; 2005 Jul; 353(1):46-57. PubMed ID: 16000355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Association With Lipoprotein(a).
    Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
    Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipoprotein(a) as a cardiovascular risk factor].
    van Lennep JE; Mulder MT
    Ned Tijdschr Geneeskd; 2011; 155(42):A3582. PubMed ID: 22027461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants.
    Wild SH; Fortmann SP; Marcovina SM
    Arterioscler Thromb Vasc Biol; 1997 Feb; 17(2):239-45. PubMed ID: 9081676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype.
    Guo HC; Chapman MJ; Bruckert E; Farriaux JP; De Gennes JL
    Atherosclerosis; 1991 Jan; 86(1):69-83. PubMed ID: 1829609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a): a unique risk factor for cardiovascular disease.
    Anuurad E; Boffa MB; Koschinsky ML; Berglund L
    Clin Lab Med; 2006 Dec; 26(4):751-72. PubMed ID: 17110238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations among serum lipoprotein(a) levels, apolipoprotein(a) phenotypes, and myocardial infarction in patients with extremely low and high levels of serum lipoprotein(a).
    Saku K; Zhang B; Liu R; Shirai K; Arakawa K
    Jpn Circ J; 1999 Sep; 63(9):659-65. PubMed ID: 10496479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
    Tsimikas S; Hall JL
    J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship among apolipoprotein(a) polymorphisms, the low-density lipoprotein receptor-related protein, and the very low density lipoprotein receptor genes, and plasma lipoprotein(A) concentration in the Czech population.
    Benes P; Muzík J; Benedík J; Znojil V; Vácha J
    Hum Biol; 2002 Feb; 74(1):129-36. PubMed ID: 11931574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.